Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 11, 2007 - Issue 12
Submit an article Journal homepage
113
Views
19
CrossRef citations to date
0
Altmetric
Review

Targeting platelets for prevention and treatment of cardiovascular disease

Todd A Duhamel University of Manitoba, Institute of Cardiovascular Sciences, St Boniface General Hospital Research Center, Department of Physiology, Faculty of Medicine, 351 Tache Avenue, Winnipeg, Manitoba, R2H 2A6, Canada +1 204 235 3417; +1 204 233 6723; [email protected]
, PhD,
Yan-Jun Xu University of Manitoba, Institute of Cardiovascular Sciences, St Boniface General Hospital Research Center, Department of Physiology, Faculty of Medicine, 351 Tache Avenue, Winnipeg, Manitoba, R2H 2A6, Canada +1 204 235 3417; +1 204 233 6723; [email protected]
, MD PhD,
Amarjit S Arneja University of Manitoba, Institute of Cardiovascular Sciences, St Boniface General Hospital Research Center, Department of Internal Medicine, Faculty of Medicine, Winnipeg, Canada
, MD &
Naranjan S Dhalla University of Manitoba, Institute of Cardiovascular Sciences, St Boniface General Hospital Research Center, Department of Physiology, Faculty of Medicine, 351 Tache Avenue, Winnipeg, Manitoba, R2H 2A6, Canada +1 204 235 3417; +1 204 233 6723; [email protected]
, PhD MD DSc
Pages 1523-1533 | Published online: 18 Nov 2007

Bibliography

  • TRAN H, ANAND SS: Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA (2004) 292:1867-1874.
  • SAINI HK, XU YJ, ARNEJA AS et al.: Pharmacological basis of different targets for the treatment of atherosclerosis. J. Cell Mol. Med. (2005) 9:818-839.
  • THAULOW E, ERIKSSEN J, SANDVIK L et al.: Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation (1991) 84:613-617.
  • JEREMY JY, SHUKLA N, WAN S et al.: The pathobiology of endothelin-1 in vein graft disease: are ETA receptor antagonists the solution to prevent vein graft failure? Curr. Vasc. Pharmacol. (2005) 3:315-323.
  • TANGELDER MJ, LAWSON JA, ALGRA A, EIKELBOOM BC: Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery. J. Vasc. Surg. (1999) 30:701-709.
  • DORFFLER-MELLY J, BULLER HR, KOOPMAN MM, PRINS MH: Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. Cochrane Database Syst. Rev. (2003):CD000536.
  • RODRIGUES HL: Update on the treatment with platelet antiaggregation agents. Rev. Port. Cardiol. (2001) 20:79-95.
  • BEAMISH RE, DHILLON KS, SINGAL PK, DHALLA NS: Protective effect of sulfinpyrazone against catecholamine metabolite adrenochrome-induced arrhythmias. Am. Heart J. (1981) 102:149-152.
  • MUNZEL TF, POST F: Pathogenesis and therapy of the acute coronary syndrome: differentiated advantage of glycoprotein IIb/IIIa receptor antagonists for high-risk patients. Dtsch Med. Wochenschr. (2006) 131:S215-S218.
  • KANDZARI DE: Future perspectives on antithrombin and antiplatelet therapies: novel antiplatelet and antithrombin therapies. Rev. Cardiovasc. Med. (2006) 7(Suppl. 3):S43-S52.
  • MACIA BC, RONZON FA, FERNANDEZ GE: Aspirin for the primary prevention of cardiovascular diseases in diabetic patients. A review of currently available tests. Rev. Esp. Salud Publica (2006) 80:613-620.
  • VALLES J, SANTOS MT, FUSET MP et al.: Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction. Am. J. Cardiol. (2007) 99:19-25.
  • FARADAY N, BECKER DM, YANEK LR et al.: Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am. J. Cardiol. (2006) 98:774-779.
  • KROTZ F, HELLWIG N, SCHIELE TM et al.: Prothrombotic potential of NSAID in ischemic heart disease. Mini Rev. Med. Chem. (2006) 6:1351-1355.
  • COOKE GE, GOLDSCHMIDT-CLERMONT PJ: The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease. Expert Opin. Drug Saf. (2006) 5:815-826.
  • SAINI HK, TAKEDA N, GOYAL RK et al.: Therapeutic potentials of sarpogrelate in cardiovascular disease. Cardiovasc. Drug Rev. (2004) 22:27-54.
  • SHARMA SK, ZAHRADKA P, CHAPMAN D et al.: Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate. J. Pharmacol. Exp. Ther. (1999) 290:1475-1481.
  • ZHANG M, XU YJ, MENGI S et al.: Therapeutic potential of pentoxifylline for treatment of cardiovascular diseases. Exp. Clin. Cardiol. (2004) 9:103-111.
  • BATH PM, BATH-HEXTALL FJ: Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke. Cochrane Database Syst. Rev. (2004):CD000162.
  • LUMSDEN AB, RICE YW: Medical management of peripheral arterial disease: a therapeutic algorithm. J. Endovasc. Ther. (2006) 13:II19-II29.
  • BATCHELDER K, MAYOSI BM: Pentoxifylline for heart failure: a systematic review. S. Afr. Med. J. (2005) 95:171-175.
  • THIBONNIER M, KILANI A, RAHMAN M et al.: Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients. Hypertension (1999) 34:1293-1300.
  • WANG J, GUO X, DHALLA NS: Modification of myosin protein and gene expression in failing hearts due to myocardial infarction by enalapril or losartan. Biochim. Biophys. Acta (2004) 1690:177-184.
  • SATO Y, FUJII S, IMAGAWA S et al.: Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers. J. Atheroscler. Thromb. (2007) 14:31-35.
  • KALINOWSKI L, MATYS T, CHABIELSKA E et al.: Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension (2002) 40:521-527.
  • NUNEZ A, GOMEZ J, ZALBA LR et al.: Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan. J. Renin Angiotensin Aldosterone Syst. (2000) 1:175-179.
  • KRAMER C, SUNKOMAT J, WITTE J et al.: Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ. Res. (2002) 90:770-776.
  • WELLES EG, BOUDREAUX MK, TYLER JW: Platelet, antithrombin, and fibrinolytic activities in taurine-deficient and taurine-replete cats. Am. J. Vet. Res. (1993) 54:1235-1243.
  • HAYES KC, PRONCZUK A, ADDESA AE, STEPHAN ZF: Taurine modulates platelet aggregation in cats and humans. Am. J. Clin. Nutr. (1989) 49:1211-1216.
  • NIEMI TT, MUNSTERHJELM E, POYHIA R et al.: The effect of N-acetylcysteine on blood coagulation and platelet function in patients undergoing open repair of abdominal aortic aneurysm. Blood Coagul. Fibrinolysis (2006) 17:29-34.
  • SHEN L, CUI Y: Effects of the leaf of Ginkgo biloba L. extract on blood rheology in animals. Zhongguo Zhong Yao Za Zhi (1998) 23:622.
  • KUDOLO GB, WANG W, BARRIENTOS J et al.: The ingestion of Ginkgo biloba extract (EGb 761) inhibits arachidonic acid-mediated platelet aggregation and thromboxane B2 production in healthy volunteers. J. Herb. Pharmacother. (2004) 4:13-26.
  • JIN YR, YU JY, LEE JJ et al.: Antithrombotic and antiplatelet activities of Korean red ginseng extract. Basic Clin. Pharmacol. Toxicol. (2007) 100:170-175.
  • KIMURA Y, OKUDA H, ARICHI S: Effects of various ginseng saponins on 5-hydroxytryptamine release and aggregation in human platelets. J. Pharm. Pharmacol. (1988) 40:838-843.
  • HOKAMA Y, HOKAMA JL: In vitro inhibition of platelet aggregation with low dalton compounds from aqueous dialysates of edible fungi. Res. Commun. Chem. Pathol. Pharmacol. (1981) 31:177-180.
  • THOMSON M, AL QATTAN KK, AL SAWAN SM et al.: The use of ginger (Zingiber officinale Rosc.) as a potential anti-inflammatory and antithrombotic agent. Prostaglandins Leukot. Essent. Fatty Acids (2002) 67:475-478.
  • KUKOBA TV, SHYSH AM, MOIBENKO OO et al.: The effects of α-linolenic acid on the functioning of the isolated heart during acute myocardial ischemia/reperfusion. Fiziol Zh (2006) 52:12-20.
  • MEADOWS TA, BHATT DL: Clinical aspects of platelet inhibitors and thrombus formation. Circ. Res. (2007) 100:1261-1275.
  • VAN OEVEREN W, HARDER MP, ROOZENDAAL KJ et al.: Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. (1990) 99:788-796.
  • MANGANO DT, TUDOR IC, DIETZEL C: The risk associated with aprotinin in cardiac surgery. N. Engl. J. Med. (2006) 354:353-365.
  • ULKER S, MCKEOWN PP, BAYRAKTUTAN U: Aprotinin impairs coronary endothelial function and down-regulates endothelial NOS in rat coronary microvascular endothelial cells. Cardiovasc. Res. (2002) 55:830-837.
  • SAMAMA CM, MAZOYER E, BRUNEVAL P et al.: Aprotinin could promote arterial thrombosis in pigs: a prospective randomized, blind study. Thromb. Haemost. (1994) 71:663-669.
  • DRAZEN JM: Research replication. N. Engl. J. Med. (2006) 355:2252-2253.
  • THIBONNIER M, KILANI A, RAHMAN M et al.: Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients. Hypertension (1999) 34:1293-1300.
  • SHARMA SK, DEL RIZZO DF, ZAHRADKA P et al.: Sarpogrelate inhibits serotonin-induced proliferation of porcine coronary artery smooth muscle cells: implications for long-term graft patency. Ann. Thorac. Surg. (2001) 71:1856-1864.
  • TEMSAH RM, KUMAMOTO H, TAKEDA N, DHALLA NS: Sarpogrelate diminishes changes in energy stores and ultrastructure of the ischemic–reperfused rat heart. Can. J. Physiol. Pharmacol. (2001) 79:761-767.
  • BRASIL D, TEMSAH RM, KUMAR K et al.: Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats. J. Cardiovasc. Pharmacol. Ther. (2002) 7:53-59.
  • ZHANG M, XU YJ, SAINI HK et al.: Pentoxifylline attenuates cardiac dysfunction and reduces TNF-α level in ischemic–reperfused heart. Am. J. Physiol. Heart Circ. Physiol. (2005) 289:H832-H839.
  • ZHANG M, XU YJ, SAINI HK et al.: TNF-α as a potential mediator of cardiac dysfunction due to intracellular Ca2+-overload. Biochem. Biophys. Res. Commun. (2005) 327:57-63.
  • AUKRUST P, YNDESTAD A, UELAND T et al.: Anti-inflammatory trials in chronic heart failure. Heart Fail. Monit. (2006) 5:2-9.
  • PASCARELLA L, SCHONBEIN GW, BERGAN JJ: Microcirculation and venous ulcers: a review. Ann. Vasc. Surg. (2005) 19:921-927.
  • PRASAD K, LEE P: Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism. Atherosclerosis (2007) 192:313-322.
  • XU YJ, AZIZ OA, BHUGRA P et al.: Potential role of lysophosphatidic acid in hypertension and atherosclerosis. Can. J. Cardiol. (2003) 19:1525-1536.
  • XU YJ, RATHI SS, ZHANG M et al.: Mechanism of the positive inotropic effect of lysophosphatidic acid in rat heart. J. Cardiovasc. Pharmacol. Ther. (2002) 7:109-115.
  • XU YJ, RATHI SS, CHAPMAN DC et al.: Mechanisms of lysophosphatidic acid-induced DNA synthesis in vascular smooth muscle cells. J. Cardiovasc. Pharmacol. (2003) 41:381-387.
  • BIRGBAUER E, CHUN J: New developments in the biological functions of lysophospholipids. Cell Mol. Life Sci. (2006) 63:2695-2701.
  • WEI L: Lysophospholipid signaling in cardiac myocyte hypertrophy. J. Mol. Cell Cardiol. (2004) 36:465-468.
  • OKUSA MD, YE H, HUANG L et al.: Selective blockade of lysophosphatidic acid LPA3 receptors reduces murine renal ischemia–reperfusion injury. Am. J. Physiol. Renal Physiol. (2003) 285:F565-F574.
  • TSUDA S, OKUDAIRA S, MORIYA-ITO K et al.: Cyclic phosphatidic acid is produced by autotaxin in blood. J. Biol. Chem. (2006) 281:26081-26088.
  • MURAKAMI-MUROFUSHI K, UCHIYAMA A, FUJIWARA Y et al.: Biological functions of a novel lipid mediator, cyclic phosphatidic acid. Biochim. Biophys. Acta (2002) 1582:1-7.
  • MCNEILL JR: Role of vasopressin in the control of arterial pressure. Can. J. Physiol. Pharmacol. (1983) 61:1226-1235.
  • LEMMENS-GRUBER R, KAMYAR M: Vasopressin antagonists. Cell Mol. Life Sci. (2006) 63:1766-1779.
  • STREEFKERK JO, VAN ZWIETEN PA: Vasopressin receptor antagonists: pharmacological tools and potential therapeutic agents. Auton. Autacoid Pharmacol. (2006) 26:141-148.
  • XU YJ, GOPALAKRISHNAN V: Vasopressin increases cytosolic free [Ca2+] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors. Circ. Res. (1991) 69:239-245.
  • GHEORGHIADE M: The clinical effects of vasopressin receptor antagonists in heart failure. Cleve. Clin. Med. (2007) 73:S24-S29.
  • ROSSI J, ORLANDI C, GHEORGHIADE M: Vasopressin antagonists in the management of heart failure. Expert Rev. Cardiovasc. Ther. (2007) 5:323-330.
  • SERRADEIL-LE GAL C, WAGNON J, GARCIA C et al.: Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J. Clin. Invest. (1993) 92:224-231.
  • BROUARD R, LAPORTE V, SERRADEIL LG et al.: Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers. Adv. Exp. Med. Biol. (1998) 449:455-465.
  • SOLBERG OG, OMLAND T: Arginine vasopressin antagonism – new treatment option in chronic heart failure. Tidsskr Nor Laegeforen (2007) 127:179-182.
  • TRASK AJ, FERRARIO CM: Angiotensin-(1 – 7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc. Drug Rev. (2007) 25:162-174.
  • ISHIKAWA M, SEKIZUKA E, YAMAGUCHI N et al.: Angiotensin II type 1 receptor signaling contributes to platelet–leukocyte–endothelial cell interactions in the cerebral microvasculature. Am. J. Physiol. Heart Circ. Physiol. (2007) 292:H2306-H2315.
  • XIE XM, YU GL, ZHOU P: Effect of losartan and amilodipine on the platelet activation and renal function in patients with mild and moderate hypertension. Hunan Yi Ke Da Xue Xue Bao (2002) 27:130-132.
  • ENGLER MM, ENGLER MB: Omega-3 fatty acids: role in cardiovascular health and disease. J. Cardiovasc. Nurs. (2006) 21:17-24.
  • RAMAPRASAD TR, BASKARAN V, KRISHNAKANTHA TP, LOKESH BR: Modulation of antioxidant enzyme activities, platelet aggregation and serum prostaglandins in rats fed spray-dried milk containing n-3 fatty acid. Mol. Cell Biochem. (2005) 280:9-16.
  • GAMEZ R, MAZ R, ARRUZAZABALA ML et al.: Effects of concurrent therapy with policosanol and omega-3 fatty acids on lipid profile and platelet aggregation in rabbits. Drugs R&D (2005) 6:11-19.
  • FERRIER LK, CASTON LJ, LEESON S et al.: α-Linolenic acid- and docosahexaenoic acid-enriched eggs from hens fed flaxseed: influence on blood lipids and platelet phospholipid fatty acids in humans. Am. J. Clin. Nutr. (1995) 62:81-86.
  • ALLMAN MA, PENA MM, PANG D: Supplementation with flaxseed oil versus sunflowerseed oil in healthy young men consuming a low fat diet: effects on platelet composition and function. Eur. J. Clin. Nutr. (1995) 49:169-178.
  • HU FB, MANSON JE, WILLETT WC: Types of dietary fat and risk of coronary heart disease: a critical review. J. Am. Coll. Nutr. (2001) 20:5-19.
  • FREESE R, MUTANEN M, VALSTA LM, SALMINEN I: Comparison of the effects of two diets rich in monounsaturated fatty acids differing in their linoleic/α-linolenic acid ratio on platelet aggregation. Thromb. Haemost. (1994) 71:73-77.
  • LI D, SINCLAIR A, WILSON A et al.: Effect of dietary α-linolenic acid on thrombotic risk factors in vegetarian men. Am. J. Clin. Nutr. (1999) 69:872-882.
  • WANG C, HARRIS WS, CHUNG M et al.: n-3 Fatty acids from fish or fish-oil supplements, but not α-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am. J. Clin. Nutr. (2006) 84:5-17.
  • DENG YK, WEI F, LI YN: Effects of Ginkgo biloba extract (ginaton) on mRNA expression of bcl-2 and bcl-xL in myocardium of patients underwent hypothermic cardiopulmonary bypass. Zhongguo Zhong Xi Yi Jie He Za Zhi (2007) 27:256-258.
  • YEH GY, DAVIS RB, PHILLIPS RS: Use of complementary therapies in patients with cardiovascular disease. Am. J. Cardiol. (2006) 98:673-680.
  • LIU Z, LI Z, LIU X: Effect of ginsenoside Re on cardiomyocyte apoptosis and expression of Bcl-2/Bax gene after ischemia and reperfusion in rats. J. Huazhong Univ. Sci. Technolog. Med. Sci. (2002) 22:305-309.
  • XU YJ, CHEN Z, LIU J et al.: Effect of panaxadiol saponins on blood rheology. Yao Xue Tong Bao (1988) 23:284-286.
  • YU JY, JIN YR, LEE JJ et al.: Antiplatelet and antithrombotic activities of Korean red ginseng. Arch. Pharm. Res. (2006) 29:898-903.
  • YUN YP, DO JH, KO SR et al.: Effects of Korean red ginseng and its mixed prescription on the high molecular weight dextran-induced blood stasis in rats and human platelet aggregation. J. Ethnopharmacol. (2001) 77:259-264.
  • AGARWAL KC, RUSSO FX, PARKS RE Jr: Inhibition of human and rat platelet aggregation by extracts of Mo-er (Auricularia auricula). Thromb. Haemost. (1982) 48:162-165.
  • NURTJAHJA-TJENDRAPUTRA E, AMMIT AJ, ROUFOGALIS BD et al.: Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger. Thromb. Res. (2003) 111:259-265.
  • KOO KL, AMMIT AJ, TRAN VH et al.: Gingerols and related analogues inhibit arachidonic acid-induced human platelet serotonin release and aggregation. Thromb. Res. (2001) 103:387-397.
  • NARDINI M, NATELLA F, SCACCINI C: Role of dietary polyphenols in platelet aggregation. A review of the supplementation studies. Platelets (2007) 18:224-243.
  • HOLT RR, ACTIS-GORETTA L, MOMMA TY, KEEN CL: Dietary flavanols and platelet reactivity. J. Cardiovasc. Pharmacol. (2006) 47(Suppl. 2):S187-S196.
  • MENNEN LI, SAPINHO D, DE BREE A et al.: Consumption of foods rich in flavonoids is related to a decreased cardiovascular risk in apparently healthy French women. J. Nutr. (2004) 134:923-926.
  • ARTS IC, HOLLMAN PC: Polyphenols and disease risk in epidemiologic studies. Am. J. Clin. Nutr. (2005) 81:S317-S325.
  • HEPTINSTALL S, MAY J, FOX S et al.: Cocoa flavanols and platelet and leukocyte function: recent in vitro and ex vivo studies in healthy adults. J. Cardiovasc. Pharmacol. (2006) 47(Suppl. 2):S197-S205.
  • RICE-EVANS CA, MILLER NJ, PAGANGA G: Structure–antioxidant activity relationships of flavonoids and phenolic acids. Free Radic. Biol. Med. (1996) 20:933-956.
  • MIYATA K, SHIMOKAWA H, HIGO T et al.: Sarpogrelate, a selective 5-HT2A serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model. J. Cardiovasc. Pharmacol. (2000) 35:294-301.
  • MILICIC D: ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome. Acta Med. Croatica (2004) 58:129-134.
  • GRIMM W: What is evidence-based, what is new in medical therapy of acute heart failure? Herz (2006) 31:771-779.
  • VALGIMIGLI M, AGOSTONI P, SERRUYS PW: Acute coronary syndromes: an emphasis shift from treatment to prevention; and the enduring challenge of vulnerable plaque detection in the cardiac catheterization laboratory. J. Cardiovasc. Med. (2007) 8:221-229.
  • BOREK C: Garlic reduces dementia and heart-disease risk. J. Nutr. (2006) 136:S810-S812.
  • RAHMAN K, LOWE GM: Garlic and cardiovascular disease: a critical review. J. Nutr. (2006) 136:S736-S740.
  • ALLISON GL, LOWE GM, RAHMAN K: Aged garlic extract and its constituents inhibit platelet aggregation through multiple mechanisms. J. Nutr. (2006) 136:S782-S788.
  • ANDER BP, WEBER AR, RAMPERSAD PP et al.: Dietary flaxseed protects against ventricular fibrillation induced by ischemia–reperfusion in normal and hypercholesterolemic rabbits. J. Nutr. (2004) 134:3250-3256.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.